Metropolis Healthcare LtdNSE:METROPOLIS
Current view Q4 2026
Diagnostics chain; the flashy 24% growth came mostly from buying labs. Real underlying growth is only ~12% and the promised profit-margin improvement has never arrived.
Latest exchange filings last 5 · 5 after Q4 2026
- 9 Sep ’26Allotment of 66,312 equity shares under the Metropolis- Restrictive Stock Unit Plan, 2020 ↗
- 7 Sep ’26MQSPL signed SSA and SHA with Medsource and Dr. Puneet; total investment about INR 1.26 crore. ↗
- 7 Sep ’26Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 7 Sep ↗
- 2 Sep ’26Transcript of Investors & Analyst Meet held on Thursday, August 27, 2026 ↗
- 27 Aug ’26Audio recording of Investors & Analyst Meet held on August 27, 2026 uploaded on company website. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +23.2% | +4.7% | +12.8% | +10.5% |
| Operating profit | ▲ +74.2% | +13.7% | +11.1% | +6.9% |
| EPS | ▲ +74.5% | +23.0% | +9.5% | +0.5% |
| PAT | ▲ +75.9% | +21.4% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +23.2%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average62/100
Growing, but too slowly to re-price. Profit per share grew 10% a year. A big re-pricing usually needs more than 15% a year, so the score is capped no matter how cheap it looks.
₹572 → ₹1,145 needs the P/E at 95× — it is 62× today, and has ranged 34× to 98× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 143× — never traded above 98× in 5 years.
Re-rated already, on growth that doesn't fully back it.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a mid-cap at ₹12,054 cr, so the odds of a re-rate are not fighting its own size.
Band capped: growth of 9.5% is below the 15% bar a re-rate needs.
Growth rate used: 9.5% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Healthcare · 6 of 17 listed
It earns 18% on its capital, fourth of 6, and it is the third most expensive of the 6 shown.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Metropolis Healt | ₹594 | 59.2× | ₹12,319 Cr | 17.8% | +25.8% | +16.6% |
| Dr Lal Pathlabs | ₹1,922 | 57.4× | ₹32,261 Cr | 28.0% | +28.0% | +19.1% |
| Vijaya Diagnost. | ₹1,552 | 85.3× | ₹15,983 Cr | 20.5% | +37.6% | +22.8% |
| Thyrocare Tech. | ₹557 | 49.0× | ₹8,862 Cr | 35.4% | +34.1% | +24.3% |
| Nephrocare Health Services | ₹742 | 87.7× | ₹7,461 Cr | 15.3% | +34.9% | +23.7% |
| Suraksha Diagno. | ₹336 | 48.9× | ₹1,750 Cr | 17.3% | +38.4% | +20.8% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — a little wider than 3 years earlier | operating margin 23% → 25% over 3 years |
|---|---|---|
| Did the profit turn into cash? | more than all of it — reserves released cash too | 98% last year, 101% over three · free cash flow ₹300 cr, positive in 5 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹232 cr — 0.15× its own equity (was 0.15×) |
| Is it being collected? | collection is steady | 38 days to collect, down 3 in a year · cash cycle −57 days |
| Who has been buying? | the promoters have held steady | promoters 48.9%, 49.8% → 48.9% over 2.8 years · FIIs 11.0% (−1.8) · DIIs 35.1% (+2.7) · shareholders 86,249 → 50,636 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 17.8% · ROE 13.6% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
Against it
- Stock is trading at 8.17 times its book value
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 12.4% over last 3 years.
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.